DailyIQ
|
Sector:HealthcareAll sectors
Last updated 2 minutes ago

COO·The Cooper Companies, Inc.

$.
-. (-.%)
After Hours
High
$71.39
Open
$70.83
Market Cap
13.79B
52W High
$89.83
Low
$70.43
P. Close
$70.71
P/E
58.48
52W Low
$58.89
Fwd P/E
14.15
DailyIQ Est.
$82.37
Technical Score (1D)
59
BUY
News Sentiment
58
BULLISH
Citigroup has kept a neutral rating on COO while lifting its price target to $76, reflecting confidence in the company’s fundamentals. This upgrade signals that analysts see upside potential, and traders should treat the new target as a valuation benchmark. Argus Research has upgraded COO to a BUY rating, citing a stronger earnings outlook and improved gross margin trajectory. The BUY rating could spur buying interest and lift analyst consensus estimates, so watch for any shifts in short‑term price momentum. The company’s 2025 sustainability report now includes Scope 3 emissions data, enhancing transparency on indirect emissions and potentially influencing ESG ratings. ESG investors may react to the disclosure, so monitor any changes in the company’s ESG score or regulatory scrutiny. COO’s premium lens and myopia control lines are driving growth, but weaker demand in Asia‑Pacific markets and margin pressure from cost inflation temper expectations. These regional headwinds could affect short‑term earnings guidance, so keep an eye on updates to Asia‑Pacific demand and currency risk management. Finally, Stifel’s endorsement of the CooperSurgical sale talks suggests a potential divestiture that could unlock value and shift focus to core diagnostics, so watch for the final sale price and regulatory clearance dates.
Earnings Summary
Cooper Companies, Inc. (COO) is a global medical device firm that operates primarily through its CooperVision contact‑lens division and its CooperSurgical fertility and women’s health segment, serving eye‑care professionals and women’s health providers worldwide. The company’s focus on vision care and women’s health places it within the broader healthcare sector, specifically the medical instruments and supplies industry, where product innovation and regulatory compliance drive performance. In the most recent four quarters, COO has consistently outperformed earnings estimates, reporting EPS of $0.92 in Q4 2024, $0.96 in Q1 2025, $1.10 in Q2 2025, $1.15 in Q3 2025, $1.10 in Q1 2026, and $1.21 in Q2 2026, each beating consensus forecasts. Revenue has risen from $964.7 million in Q4 2024 to $1.002 billion in Q1 2025, $1.060 billion in Q2 2025, $1.065 billion in Q3 2025, $1.023 billion in Q1 2026, and $1.081 billion in Q2 2026, reflecting a steady upward trajectory and a notable acceleration in Q2 2026 versus the prior year. The company has maintained a pattern of EPS beats across all quarters with no misses, while revenue growth has remained positive even when EPS dipped slightly in Q1 2026. Historically, COO has shown a consistent YoY revenue expansion, with EPS growth largely in line with or exceeding analyst expectations. The company’s earnings streak of six consecutive beats underscores disciplined cost management and a robust product mix, even as it navigates the transition away from its surgical unit. Recent analyst commentary highlights the ongoing sale of the CooperSurgical segment, with Stifel upgrading the stock to a Buy and Argus Research downgrading it, reflecting divergent views on the impact of the divestiture on margins and growth. These developments underscore the importance of the sale’s completion for the company’s strategic focus on its high‑margin contact‑lens business. Investors should watch for confirmation of the CooperSurgical sale, any updates to quarterly guidance on revenue and operating margins, and the company’s ability to sustain EPS growth in the next reporting period, as these factors will shape the valuation narrative moving forward.

EPS

EstBeatMiss
$0.89$0.98$1.07$1.16$1.25Q1'25Q2'25Q3'25Q1'26Q2'26Q4'25
QtrEstActual+/−
Q4'25$1.03 - -
Q2'26$1.11$1.21+9.3%
Q1'26$1.04$1.10+5.7%
Q3'25$1.11$1.15+3.3%
Q2'25$1.07$1.10+3.0%
Q1'25$0.93$0.96+3.3%

Revenue

EstBeatMiss
$990M$1.0B$1.0B$1.1B$1.1BQ1'25Q2'25Q3'25Q1'26Q2'26Q4'25
QtrEstActual+/−
Q4'25$1.0B - -
Q2'26$1.1B$1.1B+1.6%
Q1'26$1.0B$1.0B-1.2%
Q3'25 - $1.1B -
Q2'25 - $1.1B -
Q1'25 - $1.0B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

COO Stock Snapshot

COO is currently trading at $70.70, giving The Cooper Companies, Inc. a market cap of 13.79B and a P/E ratio of 58.5. Today's range spans $70.43–$71.39, with shares opening at $70.83 and moving down $0.01 (0.0%) from the prior close. DailyIQ's technical score sits at 59/100 (HOLD) with a news sentiment reading of 58/100.

Over the past year COO has traded between $58.89 and $89.83 - the current price is +20.1% off the 52-week low and -21.3% from the high. 25 analysts cover the stock with a Hold consensus and a mean 12-month target of $81.07 (range $66.00–$92.00), implying upside of +14.7%.

Neither bulls nor bears have the upper hand on The Cooper Companies, Inc. (COO) right now. Score: 59/100 (HOLD). Sentiment: neutral (58/100). Price: $70.70 (in the lower half of its 52-week range). (P/E: 58.5) At 13.79B in Healthcare market cap, the 52-week range of $58.89–$89.83 is the relevant frame - where the stock sits within that range, and whether volume confirms any directional move, matters more than the HOLD label alone.

The 52-week range of $58.89–$89.83 for COO provides the structural reference that options traders, systematic funds, and discretionary managers all anchor to — and at $70.70 (in the lower half of its 52-week range), the stock sits in a zone where the next 5–10% move will likely define which crowd was right. A HOLD signal at 59/100 and neutral news backdrop (58/100) don't break the tie yet, but they narrow the probability distribution toward the upside.